Afatinib Dimaleate (CAS 850140-73-7)

Application and positioning

Afatinib dimaleate is an irreversible inhibitor of the ErbB family (EGFR, HER2 and HER4), supplied as the dimaleate salt. It is used in oral tablets for EGFR-mutant non-small cell lung cancer, including tumours with exon 19 deletions or the L858R substitution. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Axitinib (CAS 319460-85-0)
• Cabozantinib Malate (CAS 1140909-48-3)
• Crizotinib (CAS 877399-52-5)
• Dacomitinib (CAS 1110813-31-4)
• N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitro-4-quinazolinamine (CAS 162012-67-1)
• N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine (CAS 179552-74-0)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.